Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. (linkinghub.elsevier.com)

Authors: Lenz G … Vitolo U Journal: The Lancet Published: 2026-06-20 DOI: https://doi.org/10.1016/S0140-6736(26)00866-4